CytomX Therapeutics Inc. Common Stock (CTMX)

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targ…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

69

Website

cytomx.com/

Fundamentals

1-day range

$3.21$3.41

Market cap

$690.12M

P/E (trailing)

—

P/E (forward)

-6.79

EPS (trailing)

$-0.44

Dividend yield

—

Beta

2.21

Avg. volume

3.98M

Forecasts

8 analyst ratings

CytomX Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CTMX

  CytomX Therapeutics Inc. Common Stock

  $3.22

  ▼ 5.99%
  Market cap $690.12MP/E —
  $1.9$8.21
• OCS

  Oculis Holding AG Ordinary shares

  $12.21

  ▼ 1.77%
  Market cap $689.43MP/E —
  $10.52$34.48
• CLYM

  Climb Bio Inc. Common Stock

  $14.56

  ▼ 3.32%
  Market cap $676.28MP/E —
  $1.54$18.33
• BBOT

  BridgeBio Oncology Therapeutics Inc. Common Stock

  $8.74

  ▼ 4.79%
  Market cap $660.88MP/E —
  $7$14.87
• DRUG

  Bright Minds Biosciences Inc. Common Stock

  $72.74

  ▼ 2.41%
  Market cap $723.93MP/E —
  $53.99$170
• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $747.88MP/E —
  $32.04$124.82
• PHAR

  Pharming Group N.V. ADS each representing 10 ordinary shares

  $11.7

  ▼ 0.68%
  Market cap $766.28MP/E 88.15
  $0.8338$1.82

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• CytomX Therapeutics Says FDA Granted Fast Track Designation To Varseta-M For Relapsed/Refractory Metastatic Colorectal Cancer; Plans Registrational Monotherapy Study Start In 1H 2027
  benzinga · 8/27/2026
• JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11
  Benzinga · 8/13/2026
• CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
  SeekingAlpha · 8/12/2026
• Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14
  Benzinga · 8/10/2026
• CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...
  Yahoo · 8/7/2026
• CytomX Therapeutics Q2 Earnings Call Highlights
  Yahoo · 8/7/2026
• CytomX Therapeutics (NASDAQ:CTMX) Shares Plunge After Q2 Revenue and EPS Miss Estimates
  ChartMill · 8/7/2026
• CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
  Yahoo · 8/6/2026
• CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/6/2026

• Alejandra Carvajal · August 3, 2026 · Grant

  450.0K
• Alejandra Carvajal · August 3, 2026 · Grant

  100.0K
• Fuchs Charles S. · July 24, 2026 · Grant

  118.0K
• Su Zhen · June 17, 2026 · Grant

  59.0K
• Young Matthew P. · June 17, 2026 · Grant

  59.0K
• Mohindru Mani · June 17, 2026 · Grant

  59.0K
• Halley E. Gilbert · June 17, 2026 · Grant

  59.0K
• Ashworth Alan · June 17, 2026 · Grant

  59.0K
• Meyers James R · June 17, 2026 · Grant

  59.0K
• Jones Elaine V · June 17, 2026 · Grant

  59.0K
• Christopher Ogden · June 15, 2026 · Sale

  1.6K @ $3.05
• Yu-Waye Chu · March 17, 2026 · Sale

  21.3K @ $6.42
• Sean A. McCarthy · March 17, 2026 · Sale

  119.0K @ $6.42
• Marcia Belvin · March 17, 2026 · Sale

  31.5K @ $6.42
• Christopher Ogden · March 17, 2026 · Sale

  19.3K @ $6.42

Institutional Ownership

March 31, 2026

Total shares held

195.36M

Total value held

$917.31M

Institutional holders

174